Custom Search


Monday 01 December 2003

Tiotropium: a new, long-acting agent for the management of COPD--a clinical review.

By: Crutchfield D.

Director 2004 Summer;12(3):160, 162-4

Tiotropium is a major advance in the management of COPD. Clinical trials have shown that this product administered once a day improves overall lung function, reduces dyspnea, improves quality of life, and reduces hospitalizations. It does have the common adverse effect of an increase in dry mouth. The once-a-day dosing and easy-to-use HandiHaler device should improve patient compliance. Overall, based on the product profile, tiotropium appears to be an effective first-line agent in the management of COPD in the nursing home.

Use of this site is subject to the following terms of use